Evidence map›Paper›PMID 31907633›Full record

ArticleWorld journal of urology2020

External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers.

Luca Cindolo, Riccardo Bertolo, Andrea Minervini, Francesco Sessa, Gianluca Muto, Pierluigi Bove, Matteo Vittori, Giorgio Bozzini, Pietro Castellan, Filippo Mugavero and 17 more

Abstract readMulticenter StudyValidation Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Luca CindoloUrology Department, "Villa Stuart" Private Hospital, Via Trionfale, 5952-00136, Rome, Italy. lucacindolo@virgilio.it.
Riccardo BertoloUrology Department, "San Carlo di Nancy" Hospital, Rome, Italy.ORCID http://orcid.org/0000-0003-0260-4601
Andrea MinerviniDepartment of Urology, Azienda Ospedaliera Careggi, Universitá di Firenze, Florence, Italy.
Francesco SessaDepartment of Urology, Azienda Ospedaliera Careggi, Universitá di Firenze, Florence, Italy.
Gianluca MutoDepartment of Urology, Azienda Ospedaliera Careggi, Universitá di Firenze, Florence, Italy.
Pierluigi BoveUrology Department, "San Carlo di Nancy" Hospital, Rome, Italy.
Matteo VittoriUrology Department, "San Carlo di Nancy" Hospital, Rome, Italy.
Giorgio BozziniUOC Urologia ASST Valle Olona, Busto Arsizio, Italy.
Pietro CastellanDepartment of Urology, SS. Annunziata Hospital, Chieti, Italy.
Filippo MugaveroU.O.C. Urologia Ospedale Vittorio Emanuele, Catania, Italy.
Mario FalsaperlaU.O.C. Urologia Ospedale Vittorio Emanuele, Catania, Italy.
Luigi SchipsDepartment of Urology, SS. Annunziata Hospital, Chieti, Italy.
Antonio CeliaDepartment of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.
Maida BadaDepartment of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.
Angelo PorrecaDepartment of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
Antonio PastoreUrology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Yazan Al SalhiUrology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Marco GiampaoliDepartment of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
Giovanni NovellaUrologic Clinic, University Hospital, Ospedale Policlinico, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Riccardo RizzettoUrologic Clinic, University Hospital, Ospedale Policlinico, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Nicoló TrabacchinUrologic Clinic, University Hospital, Ospedale Policlinico, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Guglielmo ManticaUrologia Ospedale San Raffaele Turro, Milano, Italy.
Giovannalberto PiniUrologia Ospedale San Raffaele Turro, Milano, Italy.
Riccardo LombardoDepartment of Urology, Ospedale Sant'Andrea-Universitá di Roma "Sapienza", Rome, Italy.
Andrea TubaroDepartment of Urology, Ospedale Sant'Andrea-Universitá di Roma "Sapienza", Rome, Italy.
Alessandro AntonelliUrologic Clinic, University Hospital, Ospedale Policlinico, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Cosimo De NunzioDepartment of Urology, Ospedale Sant'Andrea-Universitá di Roma "Sapienza", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecently, the Cormio et al. nomogram has been developed to predict prostate cancer (PCa) and clinically significant PCa using benign prostatic obstruction parameters. The aim of the present study was to externally validate the nomogram in a multicentric cohort.

methodsBetween 2013 and 2019, patients scheduled for ultrasound-guided prostate biopsy were prospectively enrolled at 11 Italian institutions. Demographic, clinical and histological data were collected and analysed. Discrimination and calibration of Cormio nomogram were assessed with the receiver operator characteristics (ROC) curve and calibration plots. The clinical net benefit of the nomogram was assessed with decision curve analysis. Clinically significant PCa was defined as ISUP grade group > 1.

resultsAfter accounting for inclusion criteria, 1377 patients were analysed. 816/1377 (59%) had cancer at final pathology (574/816, 70%, clinically significant PCa). Multivariable analysis showed age, prostate volume, DRE and post-voided residual volume as independent predictors of any PCa. Discrimination of the nomogram for cancer was 0.70 on ROC analysis. Calibration of the nomogram was excellent (p = 0.94) and the nomogram presented a net benefit in the 40-80% range of probabilities. Multivariable analysis for predictors of clinically significant PCa found age, PSA, prostate volume and DRE as independent variables. Discrimination of the nomogram was 0.73. Calibration was poor (p = 0.001) and the nomogram presented a net benefit in the 25-75% range of probabilities.

conclusionWe confirmed that the Cormio nomogram can be used to predict the risk of PCa in patients at increased risk. Implementation of the nomogram in clinical practice will better define its role in the patient's counselling before prostate biopsy.

Indexed as

NomogramsAgedBiopsyHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsRisk AssessmentNomogramsProstate biopsyProstatic hyperplasiaProstatic neoplasmsValidation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.